Avstera Therapeutics Corp.

At Avstera, our primary focus is to address the significant unmet need of cancer patients failing to respond, or later developing resistance to existing cutting-edge immunotherapies. With our proprietary pipeline of oncology programs, including an ultra-specific, AMES negative HDAC6i initially targeting Melanoma (AVS100), autologous HDAC6i activated macrophage-based cell therapy (AVS200), and novel mRNA-based cancer vaccine using TEM1 protein (AVS300), we will offer revolutionary therapies targeting solid tumors and addressing a significant unmet need across all tumor types.